Hims & Hers Health, Inc. (NYSE:HIMS) Short Interest Up 28.7% in October

Hims & Hers Health, Inc. (NYSE:HIMS) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 31,870,000 shares, an increase of 28.7% from the September 30th total of 24,760,000 shares. Currently, 18.3% of the shares of the company are short sold. Based on an average trading volume of 9,830,000 shares, the short-interest ratio is currently 3.2 days.

Insider Transactions at Hims & Hers Health

In other news, insider Michael Chi sold 2,054 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $22.00, for a total transaction of $45,188.00. Following the transaction, the insider now owns 185,326 shares in the company, valued at approximately $4,077,172. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Hims & Hers Health news, insider Soleil Boughton sold 2,334 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $17.30, for a total value of $40,378.20. Following the completion of the sale, the insider now owns 164,475 shares of the company’s stock, valued at $2,845,417.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Michael Chi sold 2,054 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $22.00, for a total transaction of $45,188.00. Following the transaction, the insider now directly owns 185,326 shares in the company, valued at $4,077,172. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 860,719 shares of company stock worth $15,194,078 over the last quarter. Company insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. bought a new position in Hims & Hers Health during the third quarter worth $604,000. Diversify Advisory Services LLC raised its position in shares of Hims & Hers Health by 14.9% in the 3rd quarter. Diversify Advisory Services LLC now owns 51,828 shares of the company’s stock worth $955,000 after acquiring an additional 6,706 shares in the last quarter. Lake Street Advisors Group LLC boosted its position in shares of Hims & Hers Health by 42.2% during the 3rd quarter. Lake Street Advisors Group LLC now owns 67,366 shares of the company’s stock valued at $1,241,000 after purchasing an additional 20,000 shares in the last quarter. Dakota Wealth Management acquired a new stake in Hims & Hers Health during the third quarter worth approximately $245,000. Finally, International Assets Investment Management LLC bought a new stake in Hims & Hers Health in the third quarter worth approximately $6,790,000. Institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on HIMS. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Piper Sandler restated a “neutral” rating and issued a $18.00 price target on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. TD Cowen raised their target price on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Finally, Truist Financial boosted their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $20.21.

Hims & Hers Health Stock Down 3.7 %

NYSE HIMS opened at $22.22 on Wednesday. The business’s fifty day moving average is $17.84 and its 200 day moving average is $17.99. Hims & Hers Health has a twelve month low of $5.65 and a twelve month high of $25.74. The company has a market cap of $4.77 billion, a price-to-earnings ratio of 277.78 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. The firm had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company’s revenue for the quarter was up 51.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.03) earnings per share. On average, research analysts anticipate that Hims & Hers Health will post 0.22 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.